Rockville's Emergent BioSolutions receives orphan drug designation for BioThrax for post-exposure prophylaxis of Anthrax Disease, and also finalized with FDA the protocols required for large scale manufacturing of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease.

Columbia's Grace launches ProVance disposable purification solution to reduce costs and time to market for biologics.

Rockville's Rexahn Pharmaceuticals announces promising preclinical results for RX-21101 showing increased efficacy and reduced toxicity, the company's first development candidate using its proprietary nano-polymer conjugate.

Clarksville's NeuroNascent successfully completes pre-IND meeting with FDA for Alzheimer's Disease therapeutic.

Baltimore's Circulomics awarded a Phase 1 SBIR to develop its new Nanobind DNA/RNA extraction technology.

Creatv Microtech, Rooster Bio, Vasoptic Medical named finalists in 2014 Maryland Incubator Company of the Year Competition.

Johns Hopkins University joins the University of Maryland as one the FDA's Centers for Excellence in Regulatory Science (CERSI)  working to speed drug development through advances in  regulatory science.  Johns Hopkins University also now is one of five Centers in the U.S. funded by NIH to develop innovative ways to identify and track influenza viruses.

Local volunteers work on genetically engineered bio-printed organisms in Baltimore Underground Science Space in advance of annual IGEM competition.

Md Bio Foundation and Montgomery College cosponsor Summer Biotechnology Camp for rising 7th and 8th graders.

Charles River - Frederick and Baltimore

Cadista - Salisbury

Pii - Hunt Valley                                                                  

Proove Biosciences CEO Brian
Meshkin and team are joined by local dignitaries at celebration of expansion into new facility in Annapolis Junction. Proove, a leader in personalized pain medication selection, dosing and evaluation has grown from 4 to 20 employees in Maryland during 2013.